MedTrace Logo

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

NCT02273375 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1415

Last updated 2025-08-12

No results posted yet for this study

Summary

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Conditions

Interventions

DRUG

MEDI4736

DRUG

Placebo

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    collaborator OTHER

  • Thoracic Oncology Group of Australasia (TOGA)

    collaborator UNKNOWN

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • National Cancer Institute (NCI), Naples

    collaborator UNKNOWN

  • Central and Eastern European Oncology Group

    collaborator OTHER

  • Dutch Society of Physicians for Pulmonology and Tuberculosis

    collaborator OTHER

  • Korean Cancer Study Group

    collaborator OTHER

  • Fundación GECP

    collaborator OTHER

  • West Japan Oncology Group (WJOG)

    collaborator UNKNOWN

  • Chinese Thoracic Oncology Group

    collaborator UNKNOWN

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Glenwood Goss · Ottawa Hospital Research Institute, Ontario, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-24
Primary Completion
2025-07-23
Completion
2026-01-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Bulgaria
  • Canada
  • China
  • France
  • Hungary
  • Italy
  • Japan
  • Netherlands
  • New Zealand
  • Poland
  • Romania
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273375 on ClinicalTrials.gov